TRIM28 and prostate cancer: This stratification in endometrial cancer, prostate cancer and ovarian cancer patients revealed a 3.2-, 1.9- and 2.8-fold average difference of TRIM28 mRNA expression levels, respectively, between the ‘High’ and ‘Low’ groups of patients (Figure 9).